Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Common Equity (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Common Equity for 7 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 68.82% to $1.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 billion, a 68.82% increase, with the full-year FY2025 number at $1.2 billion, up 68.82% from a year prior.
  • Common Equity was $1.2 billion for Q4 2025 at Beam Therapeutics, up from $966.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.2 billion in Q4 2025 to a low of $422.4 million in Q1 2021.
  • A 5-year average of $836.4 million and a median of $819.2 million in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 326.76% in 2021, then decreased 25.25% in 2024.
  • Beam Therapeutics' Common Equity stood at $826.7 million in 2021, then dropped by 11.28% to $733.5 million in 2022, then surged by 33.79% to $981.3 million in 2023, then fell by 25.25% to $733.5 million in 2024, then soared by 68.82% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Common Equity are $1.2 billion (Q4 2025), $966.0 million (Q3 2025), and $1.0 billion (Q2 2025).